Secukinumab + Placebo + Secukinumab
ApprovedActive 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-radiographic Axial Spondyloarthritis
Conditions
Non-radiographic Axial Spondyloarthritis
Trial Timeline
Mar 28, 2023 → Jun 13, 2028
NCT ID
NCT05622708About Secukinumab + Placebo + Secukinumab
Secukinumab + Placebo + Secukinumab is a approved stage product being developed by Novartis for Non-radiographic Axial Spondyloarthritis. The current trial status is active. This product is registered under clinical trial identifier NCT05622708. Target conditions include Non-radiographic Axial Spondyloarthritis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05622708 | Approved | Active |
Competing Products
4 competing products in Non-radiographic Axial Spondyloarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 52 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |